- Home
- HCI vs PHVS Comparison
HCI vs PHVS Comparison
Compare HCI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCI
- PHVS
- Stock Information
- Founded
- HCI 2006
- PHVS 2015
- Country
- HCI United States
- PHVS Switzerland
- Employees
- HCI N/A
- PHVS N/A
- Industry
- HCI Property-Casualty Insurers
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- HCI Finance
- PHVS Health Care
- Exchange
- HCI Nasdaq
- PHVS Nasdaq
- Market Cap
- HCI 1.7B
- PHVS 980.3M
- IPO Year
- HCI N/A
- PHVS 2021
- Fundamental
- Price
- HCI $146.76
- PHVS $18.60
- Analyst Decision
- HCI Strong Buy
- PHVS Buy
- Analyst Count
- HCI 4
- PHVS 6
- Target Price
- HCI $181.25
- PHVS $37.17
- AVG Volume (30 Days)
- HCI 173.4K
- PHVS 35.9K
- Earning Date
- HCI 08-07-2025
- PHVS 08-13-2025
- Dividend Yield
- HCI 1.09%
- PHVS N/A
- EPS Growth
- HCI 4.05
- PHVS N/A
- EPS
- HCI 10.46
- PHVS N/A
- Revenue
- HCI $759,870,000.00
- PHVS N/A
- Revenue This Year
- HCI $19.25
- PHVS N/A
- Revenue Next Year
- HCI $4.08
- PHVS N/A
- P/E Ratio
- HCI $14.03
- PHVS N/A
- Revenue Growth
- HCI 20.95
- PHVS N/A
- 52 Week Low
- HCI $83.65
- PHVS $11.51
- 52 Week High
- HCI $176.40
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- HCI 38.74
- PHVS 60.00
- Support Level
- HCI $139.93
- PHVS $16.72
- Resistance Level
- HCI $153.86
- PHVS $17.53
- Average True Range (ATR)
- HCI 4.82
- PHVS 0.93
- MACD
- HCI -0.77
- PHVS 0.07
- Stochastic Oscillator
- HCI 32.66
- PHVS 92.86
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.